Castle Biosciences, Inc.
CSTL
$38.63
$0.661.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -3.65% | -2.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.65% | -2.05% | |||
| Cost of Revenue | 6.12% | 7.59% | |||
| Gross Profit | -6.16% | -4.25% | |||
| SG&A Expenses | -3.72% | -0.95% | |||
| Depreciation & Amortization | 16.06% | -93.08% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.65% | -21.98% | |||
| Operating Income | -60.06% | 84.78% | |||
| Income Before Tax | -169.93% | 99.46% | |||
| Income Tax Expenses | 102.46% | -1,003.07% | |||
| Earnings from Continuing Operations | -111.08% | 117.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -111.08% | 117.50% | |||
| EBIT | -60.06% | 84.78% | |||
| EBITDA | -40.11% | -145.59% | |||
| EPS Basic | -111.00% | 117.31% | |||
| Normalized Basic EPS | -195.82% | 94.71% | |||
| EPS Diluted | -113.33% | 116.60% | |||
| Normalized Diluted EPS | -202.14% | 94.82% | |||
| Average Basic Shares Outstanding | 0.55% | 1.07% | |||
| Average Diluted Shares Outstanding | -1.60% | 3.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||